Mekinist 2 mg Film-Coated Tablet Filippini - Ingliż - FDA (Food And Drug Administration)

mekinist 2 mg film-coated tablet

novartis healthcare philippines, inc. - trametinib - film-coated tablet - 2 mg

Mekinist 2mg tablets Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

mekinist 2mg tablets

novartis pharmaceuticals uk ltd - trametinib - tablet - 2mg

Mekinist 0.5mg tablets Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

mekinist 0.5mg tablets

novartis pharmaceuticals uk ltd - trametinib - tablet - 500microgram

SITAMETIN 50/850 sitagliptin (as hydrochloride monohydrate) 50 mg and metformin hydrochloride 850 mg tablet blister pack Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sitametin 50/850 sitagliptin (as hydrochloride monohydrate) 50 mg and metformin hydrochloride 850 mg tablet blister pack

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - sitametin (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

SITAMETIN 50/500 sitagliptin (as hydrochloride monohydrate) 50 mg and metformin hydrochloride 500 mg tablet blister pack Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sitametin 50/500 sitagliptin (as hydrochloride monohydrate) 50 mg and metformin hydrochloride 500 mg tablet blister pack

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - sitametin (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

SITAMETIN 50/1000 sitagliptin (as hydrochloride monohydrate) 50 mg and metformin hydrochloride 1000 mg tablet blister pack Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

sitametin 50/1000 sitagliptin (as hydrochloride monohydrate) 50 mg and metformin hydrochloride 1000 mg tablet blister pack

maple healthcare pty ltd - sitagliptin hydrochloride monohydrate, quantity: 56.688 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium fumarate; sodium stearyl phthalamate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - sitametin (sitagliptin hydrochloride monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate., [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Mekinist New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

mekinist

novartis new zealand ltd - trametinib dimethyl sulfoxide 1.127mg equivalent to trametinib 1 mg - film coated tablet - 1 mg - active: trametinib dimethyl sulfoxide 1.127mg equivalent to trametinib 1 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose magnesium stearate mannitol microcrystalline cellulose opadry white oy-s-28876 purified water sodium laurilsulfate - mekinist in combination with dabrafenib is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma. mekinist as a monotherapy is indicated for the treatment of patients with brafv600 mutation positive unresectable stage iii or metastatic (stage iv) melanoma and in whom either there is an intolerance to braf inhibitors or braf inhibitors cannot be used. mekinist as monotherapy has not demonstrated clinical activity in patients who have progressed on braf inhibitor therapy.

Mekinist tablets film-coated Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

mekinist tablets film-coated

glaxo wellcome s.a. - trametinib (trametinib dimthyl sulfoxide) - tablets film-coated - 2mg

Mekinist tablets film-coated Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

mekinist tablets film-coated

glaxo wellcome s.a. - trametinib (trametinib dimthyl sulfoxide) - tablets film-coated - 2mg

Mekinist film coated tablets 2.254 MG/1 TAB Ġordan - Ingliż - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

mekinist film coated tablets 2.254 mg/1 tab

شركة مستودع الأدوية الأردني - the jordan drugstore co - trametinib dimethyl sulfoxide 2.254 mg/1 tab - 2.254 mg/1 tab